Core Insights - The company has changed its name to Channel Therapeutics Corporation to better reflect its focus on sodium channel modulation and blockade for pain treatment [1][2] - The company has reincorporated in Nevada, expecting lower tax rates and increased strategic flexibility [4] Therapeutic Program Update - The Depot Program for Postoperative Nerve Blocks has shown sustained drug release over 96 hours in animal studies, with efficacy results expected imminently [5] - The Eye Pain Program has well-tolerated eye drops in animal studies, with efficacy results anticipated in the coming weeks and toxicology data expected by late Q1 2025, aiming to start Phase II human studies in Q2 2025 [5] - The company is exploring financing for its Chronic Pain program, expected to kick off in Q1 2025 [6] Company Overview - Channel Therapeutics Corporation is a clinical-stage biotechnology company focused on developing non-opioid, non-addictive therapeutics targeting the sodium ion-channel NaV1.7 for various pain types [7]

PART I: FINANCIAL INFORMATION [Item 1. Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) Financial statements reflect significant cash and asset growth from IPO, substantial net losses, and a going concern warning [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of September 30, 2024, cash and total assets significantly increased to **$1.25 million** and **$2.14 million** respectively, while total liabilities decreased, improving the stockholders' deficit to **$(1.43) million** Condensed Consolidated Balance Sheet Highlights (Unaudited) | Account | Sep 30, 2024 | Dec 31, 2023 | | :--- | :--- | :--- | | **Assets** | | | | Cash | $1,254,903 | $96,391 | | Total Current Assets | $2,139,888 | $96,391 | | **Total Assets** | **$2,139,888** | **$96,391** | | **Liabilities & Stockholders' Deficit** | | | | Accounts payable and accrued expenses | $1,279,487 | $4,620,925 | | Total Current Liabilities | $3,567,382 | $6,540,943 | | **Total Liabilities** | **$3,567,382** | **$6,540,943** | | Accumulated deficit | $(19,548,253) | $(13,519,649) | | **Total Stockholders' Deficit** | **$(1,427,494)** | **$(6,444,552)** | [Condensed Consolidated Statements of Operations](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For the nine months ended September 30, 2024, net loss increased to **$6.03 million** due to higher operating expenses, while net loss per share improved to **$(1.11)** Operating Results for the Nine Months Ended September 30 (Unaudited) | Metric | 2024 | 2023 | | :--- | :--- | :--- | | General and administrative expenses | $3,158,525 | $1,677,078 | | Research and development | $894,200 | $285,204 | | Total operating expenses | $5,746,401 | $2,983,469 | | **Net Loss** | **$(6,028,604)** | **$(3,341,640)** | | Net loss per common share | $(1.11) | $(3.24) | | Weighted average shares outstanding | 5,420,359 | 1,032,338 | [Condensed Consolidated Statements of Changes in Stockholders' Deficit](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders'%20Deficit) Stockholders' deficit improved from **$(6.44) million** to **$(1.43) million** primarily due to **$5.97 million** from common stock issuance, offset by a **$6.03 million** net loss - Key activities impacting stockholders' deficit in the first nine months of 2024 include the issuance of **1,100,000 shares** of common stock for **$5.97 million** cash, conversion of preferred stock and notes, and stock-based compensation expense of approximately **$1.27 million**, offset by a net loss of **$6.03 million**[8](index=8&type=chunk)[10](index=10&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities increased to **$5.12 million**, largely offset by **$6.28 million** in financing activities from the IPO, resulting in a **$1.16 million** cash increase Cash Flow Summary for the Nine Months Ended September 30 (Unaudited) | Cash Flow Activity | 2024 | 2023 | | :--- | :--- | :--- | | Net Cash Used In Operating Activities | $(5,122,219) | $(624,224) | | Net Cash Provided By Financing Activities | $6,280,731 | $591,936 | | **Net Increase (Decrease) in Cash** | **$1,158,512** | **$(32,288)** | | Cash at Beginning of Period | $96,391 | $55,074 | | **Cash at End of Period** | **$1,254,903** | **$22,786** | [Notes to Condensed Consolidated Financial Statements](index=7&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail the company's clinical-stage biotech focus, a "Going Concern" warning due to a **$6.0 million** net loss, IPO proceeds, legal proceedings, and subsequent corporate changes - The company is a clinical-stage biotech focused on developing pain therapeutics (CC8464, CT2000, CT3000) by targeting the NaV1.7 sodium ion-channel[11](index=11&type=chunk)[12](index=12&type=chunk)[13](index=13&type=chunk) - There is substantial doubt about the company's ability to continue as a going concern due to a net loss of approximately **$6.0 million** for the nine months ended Sep 30, 2024, and a working capital deficit of **$1.4 million**[21](index=21&type=chunk) - The company completed its IPO on February 21, 2024, raising approximately **$5.7 million** in net proceeds after deducting underwriting discounts and offering expenses[17](index=17&type=chunk)[89](index=89&type=chunk) - On October 3, 2024, the company was awarded a default judgment against its former CEO, Christian Kopfli, and Chromocell Holdings, allowing it to reverse a **$363,091** compensation accrual and recognize it as a gain[50](index=50&type=chunk)[123](index=123&type=chunk) - Subsequent to the quarter end, the company approved a reincorporation merger from Delaware to Nevada and a name change to 'Channel Therapeutics Corporation', expected in Q4 2024[131](index=131&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=28&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's NaV1.7 pain therapeutics pipeline, increased net loss to **$6.0 million** due to higher R&D and G&A expenses, and the need for future funding beyond Q4 2024 - The company's pipeline includes three programs based on its proprietary molecule targeting NaV1.7: CC8464 (neuropathic pain), CT2000 (eye pain), and CT3000 (post-operative pain)[137](index=137&type=chunk)[147](index=147&type=chunk)[150](index=150&type=chunk) - Management states that existing cash, including net proceeds from the IPO, is sufficient to fund operations and capital expenses only through the end of 2024, highlighting a future funding requirement[190](index=190&type=chunk) Comparison of Operating Results for the Nine Months Ended September 30 | Metric | 2024 | 2023 | Change (%) | | :--- | :--- | :--- | :--- | | General and administrative expenses | $3,158,525 | $1,677,078 | +88% | | Research and development | $894,200 | $285,204 | +214% | | **Net loss** | **$(6,028,604)** | **$(3,341,640)** | **+80%** | - The increase in R&D expenses for the nine months ended Sep 30, 2024, was primarily driven by a **$488,636** increase in Chemistry Manufacturing and Controls (CMC) services[173](index=173&type=chunk) - The company entered into a **$30 million** committed equity financing facility with Tikkun Capital LLC on July 26, 2024, to provide future funding[185](index=185&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=39&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, Chromocell Therapeutics Corporation is not required to provide the information for this item - The company is not required to provide quantitative and qualitative disclosures about market risk as it qualifies as a smaller reporting company[209](index=209&type=chunk) [Item 4. Controls and Procedures](index=39&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were ineffective as of September 30, 2024, due to material weaknesses in segregation of duties, review levels, and IT general controls - The CEO and CFO concluded that the company's disclosure controls and procedures were not effective as of September 30, 2024[211](index=211&type=chunk) - Material weaknesses identified include: - Lack of segregation of duties due to limited resources - Inability to provide multiple levels of review for financial reporting - Lack of necessary internal IT infrastructure and reliance on third-party software[212](index=212&type=chunk)[213](index=213&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=40&type=section&id=Item%201.%20Legal%20Proceedings) The company won a default judgment against its former CEO, reversing a **$363,091** accrual, and denies liability for a **$850,000** promissory note demand from Parexel International - The company obtained a default judgment against former CEO Christian Kopfli and Chromocell Holdings on October 3, 2024, allowing it to remove a **$363,091** compensation accrual and record it as a gain[218](index=218&type=chunk) - The company received a demand letter from Parexel International on July 31, 2024, seeking payment of over **$850,000** related to a promissory note between Parexel and Chromocell Holdings, but the company denies liability as it is not a party to the note[219](index=219&type=chunk) [Item 1A. Risk Factors](index=40&type=section&id=Item%201A.%20Risk%20Factors) As a smaller reporting company, Chromocell Therapeutics Corporation is not required to provide the information for this item - The company is not required to include risk factor disclosures as it is a smaller reporting company[220](index=220&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=40&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported unregistered equity sales to vendors and detailed its Q3 2024 stock repurchase activity of **86,196 shares** for approximately **$74,179**, with the plan subsequently expanded to **$750,000** - The company issued or agreed to issue shares and options to vendors for services in August and October 2024, claiming exemption from registration under the Securities Act[220](index=220&type=chunk)[221](index=221&type=chunk)[223](index=223&type=chunk) Share Repurchase Activity (Q3 2024) | Period | Total Shares Purchased | Average Price Paid per Share | | :--- | :--- | :--- | | August 2024 | 58,642 | $0.82 | | September 2024 | 27,554 | $0.94 | | **Total** | **86,196** | **$0.86** | - On August 5, 2024, the Board authorized a **$250,000** stock repurchase plan, which was amended on October 22, 2024, to increase the total value to **$750,000**[224](index=224&type=chunk) [Item 3. Defaults Upon Senior Securities](index=41&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities - None[225](index=225&type=chunk) [Item 4. Mine Safety Disclosures](index=41&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[225](index=225&type=chunk) [Item 5. Other Information](index=41&type=section&id=Item%205.%20Other%20Information) The company reported no other information for this item - None[225](index=225&type=chunk) [Item 6. Exhibits](index=42&type=section&id=Item%206.%20Exhibits) The report lists several exhibits filed with the SEC, including an amendment to the 2023 Equity Incentive Plan, CEO/CFO certifications, and Interactive Data Files (XBRL) - Exhibits filed include: - 10.1: Second Amendment to the 2023 Equity Incentive Plan - 31.1: CEO/CFO Certification (Section 302) - 32.1: CEO/CFO Certification (Section 906) - 101 & 104: Interactive Data Files (Inline XBRL)[227](index=227&type=chunk)

FREEHOLD, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced the unveiling of its injectable depot program utilizing peripheral nerve blocks for the treatment of post-operative pain. The depot program is based on the Company’s novel NaV1.7 molecule for treating chronic pain and eye pain. There are approximately 700,000 total knee replacemen ...

FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the “Board of Directors”) has authorized an amendment (the “Amendment”) to the Company’s existing stock repurchase plan (as amended, the “Repurchase Plan”) to increase the total value of shares of Chromocell’s common stock (“Common Stock”) available fo ...

Chromocell invites individuals, institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com FREEHOLD, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that Frank Knuettel, CEO, will present live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on September 19 ...

[PART I: FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%3A%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements (unaudited)](index=3&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) Unaudited Q2 2024 financials show increased net loss, improved cash from IPO, and substantial doubt about going concern [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Balance sheet as of June 30, 2024, shows increased cash and assets, reduced liabilities, and improved stockholders' deficit post-IPO Condensed Consolidated Balance Sheet Data (in USD) | Account | June 30, 2024 (Unaudited) | December 31, 2023 | | :--- | :--- | :--- | | **Assets** | | | | Cash | $2,405,098 | $96,391 | | Total Current Assets | $2,603,600 | $96,391 | | **Total Assets** | **$2,603,600** | **$96,391** | | **Liabilities & Stockholders' Deficit** | | | | Total Current Liabilities | $2,786,121 | $6,540,943 | | **Total Liabilities** | **$2,786,121** | **$6,540,943** | | Total Stockholders' Deficit | $(182,521) | $(6,444,552) | | **Total Liabilities and Stockholders' Deficit** | **$2,603,600** | **$96,391** | [Condensed Consolidated Statements of Operations](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) The company reported increased net losses for both three and six months ended June 30, 2024, primarily due to higher operating expenses post-IPO Statement of Operations Highlights (in USD) | Period | Net Loss (2024) | Net Loss (2023) | Net Loss per Share (2024) | Net Loss per Share (2023) | | :--- | :--- | :--- | :--- | :--- | | **Three Months Ended June 30** | $(1,771,619) | $(953,347) | $(0.31) | $(0.95) | | **Six Months Ended June 30** | $(4,333,949) | $(1,919,908) | $(0.83) | $(1.82) | - Total operating expenses for the six months ended June 30, 2024, were **$3.70 million**, a significant increase from **$1.69 million** in the prior-year period, primarily due to rises in general and administrative expenses and professional fees[8](index=8&type=chunk) [Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders'%20Equity%20(Deficit)) Stockholders' deficit significantly improved by June 30, 2024, primarily due to common stock issuance from the IPO and conversion of debt to equity - Key equity events in the first six months of 2024 included: issuing 1,100,000 shares for **$5.97 million** in cash from the IPO, converting all 600,000 Series A preferred shares, and converting notes payable totaling **$1.36 million** into common stock[13](index=13&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operations increased significantly, offset by substantial financing cash from the IPO, leading to a net cash increase Cash Flow Summary (Six Months Ended June 30) | Cash Flow Activity | 2024 | 2023 | | :--- | :--- | :--- | | Net Cash Used In Operating Activities | $(4,944,308) | $(366,989) | | Net Cash Provided By Financing Activities | $7,253,015 | $393,808 | | **Net Increase In Cash** | **$2,308,707** | **$26,819** | | **Cash at End of Period** | **$2,405,098** | **$81,893** | - Financing activities in 2024 were dominated by **$5.97 million** in cash from the IPO and **$1.59 million** from new loans[17](index=17&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail business focus on pain therapeutics, substantial doubt about going concern, IPO specifics, equity changes, legal proceedings, and significant subsequent financing events - **Business Focus:** The company is a clinical-stage biotech focused on developing NaV1.7 blockers for pain, with two main programs: CC8464 for neuropathic pain and CT2000 for eye pain[19](index=19&type=chunk)[20](index=20&type=chunk)[21](index=21&type=chunk) - **Going Concern:** Management has concluded there is substantial doubt about the company's ability to continue as a going concern for the next twelve months due to a net loss of approximately **$4.3 million** for the six months ended June 30, 2024, and a working capital deficit[26](index=26&type=chunk)[29](index=29&type=chunk) - **IPO and Equity:** The company completed its IPO on February 21, 2024, raising net proceeds of approximately **$5.7 million**. A 9-for-1 reverse stock split was effected on February 15, 2024[25](index=25&type=chunk)[81](index=81&type=chunk)[82](index=82&type=chunk) - **Legal Proceedings:** The company is involved in a legal dispute with its former CEO, Christian Kopfli, over termination and seeks damages. It also received a demand letter from Parexel for over **$850,000**, for which the company denies liability[105](index=105&type=chunk)[107](index=107&type=chunk) - **Subsequent Events:** In July 2024, the company secured a **$750,000** senior unsecured convertible note and entered into a committed equity financing facility for up to **$30 million**. In August 2024, a **$250,000** stock repurchase plan was authorized[108](index=108&type=chunk)[110](index=110&type=chunk)[111](index=111&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=27&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's pain therapeutics pipeline, increased operating expenses and net loss, ongoing going concern issues, and future clinical development plans - The company is focused on developing NaV1.7 blockers for pain. Key programs are CC8464 for neuropathic pain (EM and iSFN) and CT2000 for eye pain. A dose escalation trial for CC8464 is planned for Q3 2024, with a Phase 2a POC study to follow in 2025[116](index=116&type=chunk)[119](index=119&type=chunk)[120](index=120&type=chunk) Comparison of Operating Results (Three Months Ended June 30) | Expense Category | 2024 | 2023 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | General & administrative | $1,209,874 | $537,876 | $671,998 | 125% | | Research & development | $12,955 | $49,955 | $(37,000) | (74)% | | Professional fees | $541,257 | $189,329 | $351,928 | 186% | | **Total operating expenses** | **$1,764,086** | **$777,160** | **$986,926** | **127%** | Comparison of Operating Results (Six Months Ended June 30) | Expense Category | 2024 | 2023 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | General & administrative | $1,997,435 | $1,015,506 | $981,929 | 97% | | Research & development | $479,561 | $236,072 | $243,489 | 103% | | Professional fees | $1,221,072 | $440,165 | $780,907 | 177% | | **Total operating expenses** | **$3,698,068** | **$1,691,743** | **$2,006,325** | **119%** | - Management states there is substantial doubt about the company's ability to continue as a going concern. Existing cash from the IPO is expected to fund operations through the end of 2024, but additional capital will be needed[134](index=134&type=chunk)[155](index=155&type=chunk)[157](index=157&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=39&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company is not required to provide market risk disclosures as it qualifies as a smaller reporting company - The company is not required to provide disclosures about market risk as it qualifies as a smaller reporting company[171](index=171&type=chunk) [Item 4. Controls and Procedures](index=39&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were ineffective as of June 30, 2024, due to identified material weaknesses including lack of segregation of duties and insufficient review - The CEO and CFO concluded that disclosure controls and procedures were not effective as of June 30, 2024[173](index=173&type=chunk) - Identified material weaknesses include: - Lack of segregation of duties due to limited resources - Lack of multiple levels of review for financial reporting - Lack of necessary internal IT infrastructure and reliance on third-party software[174](index=174&type=chunk) [PART II. OTHER INFORMATION](index=41&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=41&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in legal disputes with its former CEO and Parexel, while a complaint from the New Jersey EDA was dismissed - The company is in a legal dispute with its former CEO, Christian Kopfli, who is seeking **$479,169** for what he claims was an improper termination. The company has sued him for breach of contract[177](index=177&type=chunk) - A complaint from the New Jersey Economic Development Authority (EDA) against 'Chromocell Corporation d/b/a Chromocell Therapeutics' was dismissed on May 24, 2024[178](index=178&type=chunk) - On July 31, 2024, the company received a demand from Parexel for approximately **$682,551** in principal plus over **$177,000** in interest on a promissory note between Parexel and Chromocell Holdings. The company denies liability[179](index=179&type=chunk) [Item 1A. Risk Factors](index=42&type=section&id=Item%201A.%20Risk%20Factors) The company is not required to provide risk factor disclosures as it qualifies as a smaller reporting company - The company is not required to provide this disclosure as it is a smaller reporting company[180](index=180&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=42&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities or use of proceeds - **None**[180](index=180&type=chunk) [Item 3. Defaults Upon Senior Securities](index=42&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities - **None**[180](index=180&type=chunk) [Item 4. Mine Safety Disclosures](index=42&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - **Not applicable**[180](index=180&type=chunk) [Item 5. Other Information](index=43&type=section&id=Item%205.%20Other%20Information) Francis Knuettel II, the company's CEO and CFO, was appointed to the Board of Directors effective August 12, 2024 - Francis Knuettel II, the company's CEO and CFO, was appointed to the Board of Directors on August 12, 2024[181](index=181&type=chunk) [Item 6. Exhibits](index=44&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including recent financing agreements and officer certifications - The report includes exhibits such as a Convertible Note agreement, a Securities Purchase Agreement, a Common Stock Purchase Agreement, and certifications by the Principal Executive and Financial Officer[184](index=184&type=chunk)

FREEHOLD, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the "Board of Directors") has authorized a stock repurchase plan (the "Repurchase Plan") of up to $250,000 of Chromocell's common stock ("Common Stock"), which represents approximately 23% of the non-affiliate float based on the closing price of the Co ...

FREEHOLD, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the "Board of Directors") has authorized a stock repurchase plan (the "Repurchase Plan") of up to $250,000 of Chromocell's common stock ("Common Stock"), which represents approximately 23% of the non-affiliate float based on the closing price of the Co ...

As part of the event, Frank Knuettel II, Chief Executive Officer and Chief Financial Officer of Chromocell, will provide a corporate overview and business outlook. In addition to the prepared remarks, interested parties will have the opportunity to submit questions live during the event. Mr. Knuettel will answer as many questions as possible in the time allowed. Chromocell Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addi ...

As part of the event, Frank Knuettel II, Chief Executive Officer and Chief Financial Officer of Chromocell, will provide a corporate overview and business outlook. In addition to the prepared remarks, interested parties will have the opportunity to submit questions live during the event. Mr. Knuettel will answer as many questions as possible in the time allowed. About Chromocell Therapeutics LR Advisors LLC. Jason Assad 678-570-6791 Jason@Chromocell.com FREEHOLD, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Chro ...